Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  AMAG Pharmaceuticals, Inc.    AMAG

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
04/24/2017 04/25/2017 04/26/2017 04/27/2017 04/28/2017 Date
23.2(c) 24.1(c) 24.5(c) 24.6(c) 24.4(c) Last
728 331 779 910 636 315 581 170 514 462 Volume
+3.57% +3.88% +1.66% +0.41% -0.81% Change
More quotes
Financials ($)
Sales 2017 644 M
EBIT 2017 291 M
Net income 2017 76,4 M
Debt 2017 381 M
Yield 2017 -
Sales 2018 535 M
EBIT 2018 225 M
Net income 2018 39,4 M
Debt 2018 316 M
Yield 2018 -
P/E ratio 2017 17,30
P/E ratio 2018 53,77
EV / Sales2017 1,90x
EV / Sales2018 2,16x
Capitalization 840 M
More Financials
Company
AMAG Pharmaceuticals, Inc. is a biopharmaceutical company that focuses on the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia.It focuses on the development and commercialization of Feraheme injection for intravenous or IV, use to treat iron... 
Sector
Pharmaceuticals
Calendar
07/27Earnings Release
More about the company
Surperformance© ratings of AMAG Pharmaceuticals, Inc.
Trading Rating : Investor Rating :
More Ratings
Latest news on AMAG PHARMACEUTICALS, INC.
04/26 AMAG Pharmaceuticals to Present at the Deutsche Bank Health Care Conference
04/25 AMAG Pharmaceuticals Appoints Arpad Simon, M.D. as Vice President of Pharmaco..
04/19 AMAG PHARMACEUTICALS TO HOST FIRST Q : 00 a.m. ET
04/17 AMAG Submits Supplemental New Drug Application to FDA for Makena® (Hydroxypro..
04/10 AMAG PHARMACEUTICALS INC. : Material Modification to Rights of Security Holders,..
04/05 AMAG PHARMACEUTICALS,INC. (NASDAQ : AMAG) Files An 8-K Completion of Acquisition..
04/05 AMAG PHARMACEUTICALS INC. : Completion of Acquisition or Disposition of Assets, ..
04/04 AMAG Pharmaceuticals Announces Closing of Exclusive Licensing Agreement With ..
03/28 AMAG Pharmaceuticals to Present at the Needham Healthcare Conference
03/14 TWO BIOTECH CATALYSTS TO WATCH RIGHT : Bioline RX Ltd (NASDAQ:BLRX) and AMAG Pha..
More news
Sector news : Pharmaceuticals - NEC
04/28DJBRISTOL MYERS SQUIBB : China Approves Bristol-Myers Dual-Drug Hepatitis C Treatm..
04/28DJBRISTOL MYERS SQUIBB : China Approves Bristol-Myers Squibb's Dual-Drug Hepatitis..
04/28 REGENERON PHARMACEUTICALS : Sanofi beats profit forecasts, upbeat on prospects f..
04/28DJSanofi 1st-Quarter Net Profit Rises on Sale of Animal-Health Unit
04/27DJASTRAZENECA : Faces Shareholder Uprising Over Changes to Executive Award
More sector news : Pharmaceuticals - NEC
Latest Tweets
04/28Up and Down the Ladder: Job Changes.. the latest comings and goings.. recogni.. 
04/26AMAG Pharmaceuticals to Present at the Deutsche Bank Health Care Conference .. 
04/21AMAG Pharmaceuticals given $40.00 PT by Jefferies Group LLC. buy rating.  
04/21AMAG Pharmaceuticals, Inc. $AMAG Given a $40.00 Price Target at Jefferies Gro.. 
04/10A Peek Into The Markets: U.S. Stock Futures…  
More tweets
Qtime:19
News from SeekingAlpha
04/05 AMAG Pharmaceuticals (AMAG) Presents At 16th Annual Needham Healthcare Confer..
04/04 Antares Pharma Set For Multiple Catalysts In 2017
04/04 AMAG Pharmaceuticals closes exclusive licensing agreement with Endoceutics fo..
03/08 AMAG Pharmaceuticals (AMAG) Presents At The Raymond James 38th Annual Institu..
02/15 BIOTECH FORUM DAILY DIGEST : Bristol-Myers On The Block? Biotech Continues To Ro..
Advertisement
Chart AMAG PHARMACEUTICALS, INC.
Duration : Period :
AMAG Pharmaceuticals, Inc. Technical Analysis Chart | AMAG | US00163U1060 | 4-Traders
Full-screen chart
Technical analysis trends AMAG PHARMACEUTIC...
Short TermMid-TermLong Term
TrendsBullishBearishNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 10
Average target price 28,7 $
Spread / Average Target 17%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
William K. Heiden Chief Executive Officer & Director
Frank E. Thomas President & Chief Operating Officer
Gino Santini Chairman
Edward H. Myles Chief Financial Officer, Treasurer & Senior VP
Julie Krop Chief Medical Officer & SVP-Regulatory Affairs
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
AMAG PHARMACEUTICALS, ..-29.89%840
JOHNSON & JOHNSON7.17%334 714
ROCHE HOLDING LTD.11.91%225 722
NOVARTIS AG3.78%202 360
PFIZER INC.4.43%201 998
MERCK & CO., INC.5.88%170 880
More Results